Trevi’s Execution Pivot: From Data to a Multi-Indication Cough Franchise

The Execution Pivot: From Data to Trials

Trevi Therapeutics entered 2026 with a clear shift from proof-of-concept to full-scale execution. The first-quarter call was dominated by the near-term initiation of two IPF-related chronic cough Phase III studies, a proposed adaptive Phase II/III in non-IPF-ILD, and a dose-ranging Phase IIb in refractory chronic cough (RCC). “Following our positive FDA meeting in the first quarter to align on our IPF-related chronic cough program, the team has finalized the study protocols for our Phase III trials and has been busy identifying global sites for both pivotal studies.” — Jennifer Good, Chief Executive Officer · 2026-05-06 The power assumptions that underpinned the successful CORAL study are now being stress-tested across a broader franchise. The upcoming SSRE for the RCC trial is a key de-risking milestone,

So the SSRE is exactly what we did with CORAL. It will be at the halfway point, looking for conditional power of 80%. If the numbers are below that, if the conditional power at that point is below 80%, we will upsize proportionately.

The company is also positioning for a rapid expansion into non-IPF-ILD, leveraging the same clinical sites and pulmonologists as the IPF program. Jennifer Good highlighted the synergies: "There are a lot of synergies with our IPF studies as these patients with non-IPF-ILD are seen in the same care centers by the same pulmonologists." This broadens the addressable population without a fundamental change in trial logistics.

Intellectual Property and Cash: Building a Durable Moat

Trevi’s advancement in patent issued this quarter is more than administrative; it extends protection through 2039 with potential further coverage through 2046. Jennifer noted the strategy of building out label-enabling patents around the base method-of-treatment claims. The cash position is equally compelling. David Hastings confirmed, “We ended the first quarter of 2026 with approximately $172 million in cash, cash equivalents and marketable securities. This balance does not include the $162 million in net proceeds from our underwritten common stock offering completed in April 2026.” — David Hastings, Chief Financial Officer · 2026-05-06 This runway extension into 2030 funds not only the IPF Phase III but also the RCC Phase IIb and a potential subsequent Phase III. The company's recent equity raise effectively removes the financing overhang as the pipeline approaches multiple high-value value inflection points.

Competitive Landscape and Placebo Dynamics

The imminent readout of a rival P2X3 antagonist in RCC is a double-edged sword. Farrell Simon was optimistic: "We have strong differentiation with our central and peripheral mechanism of action." Earlier, in the previous call, Jim Cassella had noted, “We had about a 17% placebo response in terms of objective cough.” — James Cassella, Chief Development Officer · 2026-03-17 That prior experience is now guiding the design of the RCC study, which incorporates a placebo run-in to control variability. Jennifer also made clear that Trevi would not be swayed by the competitor’s outcome, stating that the company would focus on its own data. The focus on placebo response and patient selection is a deliberate attempt to maintain the robust effect sizes seen in CORAL.

The pipeline’s breadth is further underscored by upcoming dyspnea data to be presented at ATS, which could bolster the commercial story. The recent stock performance reflects optimism on these execution milestones, with a 36% gain over the last 90 days.